Your session is about to expire
← Back to Search
Vismodegib + Erlotinib (+/- Gemcitabine) for Pancreatic Cancer
Study Summary
This trial is studying the side effects and best dose of a cancer drug when given with another cancer drug, with or without another drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 trial • 29 Patients • NCT01664897Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You need to have a certain amount of a type of white blood cell called neutrophils in your blood.My solid tumor cannot be surgically removed, has no other treatment options, or I refuse standard treatments.My pancreatic cancer has spread and can be biopsied.I can take care of myself and am up and about more than half of the day.You are expected to live for at least 12 weeks.You need to have a negative pregnancy test within the last 7 days before joining the study.Your AST levels are not more than three times the upper limit of normal.Your creatinine level is not more than 1.5 times the upper limit of normal.Your hemoglobin level is at least 9.0 grams per deciliter.Your blood clotting level is normal.There is a known treatment that could cure or extend my life.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.I can swallow pills or receive them through a G-tube.I agree to use effective birth control and not smoke.You must have at least 100,000 platelets per microliter of blood.Your bilirubin level is within the normal range.Criterion: You cannot have received certain types of treatments within specific time frames before the study. You also cannot have certain medical conditions or be taking certain medications. Additionally, if you are pregnant, nursing, or not using reliable birth control, you cannot participate. If you have certain heart conditions, eye abnormalities, or have had specific prior treatments, you may not be eligible to participate.
- Group 1: Treatment (vismodegib, erlotinib hydrochloride, gemcitabine)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current capacity for enrolment in this clinical trial?
"As of September 20th 2022, this clinical trial has ceased recruitment. The initial posting was on March 31st 2009. If you're seeking other medical studies involving pancreatic carcinoma, 3041 trials are actively recruiting and there are 494 Erlotinib Hydrochloride studies looking for participants."
Could you inform me as to how many sites are actively administering this trial?
"Currently, 4 sites are enrolling participants for this trial: Rochester, Scottsdale, Orlando and a few other locations. To minimise travel needs if you join the study, it is advised to select the nearest clinic possible."
Are there any recorded precedents for Erlotinib Hydrochloride trials?
"At the present moment, Erlotinib Hydrochloride is being studied in 494 clinical trials, with 138 of them at Phase 3. Woolloongabba, Queensland houses several studies on this substance; however there are 29560 other sites conducting research into it as well."
Are there any hazardous effects associated with the ingestion of Erlotinib Hydrochloride?
"Erlotinib Hydrochloride, which is still in the early stages of clinical trials, has been ranked as having a low level of safety and efficacy by our team at Power; its score on the 1 to 3 scale being only 1."
For what medical treatments is Erlotinib Hydrochloride the primary therapeutic agent?
"Erlotinib Hydrochloride has proven to be an efficacious treatment for bladder cancer, small cell lung carcinoma (SCLC), and head and neck tumours."
Are there any vacant positions in this medical study?
"As of this moment, the clinical trial referenced on clinicaltrials.gov is not recruiting patients; however, a last edited date was noted as September 20th 2022. Despite this particular study being inactive at present, there are currently 3535 other medical studies searching for participants to join them in their research efforts."
Share this study with friends
Copy Link
Messenger